Moderna Stock Rises After Promising Melanoma Data

The news sparked noticeable movement in financial markets: Moderna shares surged sharply after the results were announced. Merck shares also rose, though by a smaller margin. Traders pointed to the importance a first successful cancer vaccine would have for the business models of both companies.

Background: mRNA Cancer Vaccines

Intismeran autogene is an individualized mRNA cancer vaccine tailored to each patient's tumor tissue. Moderna gained prominence during the Covid-19 pandemic with its mRNA vaccines and has since been working on a broader vaccine pipeline targeting cancer and other diseases.

The collaboration with Merck has been in place for some time. With Keytruda, the combination approach is paired with a blockbuster drug whose patent protection is due to expire in the coming years. An approved companion vaccine could extend the therapeutic benefit of Keytruda and stabilize its revenues.

For Moderna, a market success in oncology would be an important milestone in reducing its dependence on Covid vaccines. The company has struggled with declining coronavirus revenues in recent quarters while simultaneously shouldering high research and development investments.

Significance for Moderna and Merck

Observers stressed that the newly reported results, while encouraging, do not yet demonstrate definitive efficacy. Further data and regulatory reviews are required before potential approval by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Meanwhile, demand for derivatives on Moderna shares also rose, including leveraged products and knock-out warrants, according to market data. The Dow Jones and other indices were broadly stable on the trading day.

In expert circles, combining cancer vaccines with checkpoint inhibitors such as Keytruda is considered one of the most promising fields of modern oncology. If the benefit is confirmed in the final studies, the range of therapies available to melanoma patients could be fundamentally expanded.

Outlook for Further Data

The companies announced that they will present the full study results at an upcoming medical conference. Further analyses, including on the duration of the treatment effect and potential side effects, are pending.

Market participants responded with cautious optimism: while some analysts highlighted the upside potential of Moderna shares, others pointed to the stock's historical volatility and the risk that subsequent results could fall short of expectations.